Pharma's next big discovery: AI

9 May 2018

In the latest Expert View piece on artificial intelligence (AI), Christopher Bouton, founder and chief executive of Vyasa, a provider of software for the life sciences and healthcare industries, analyzes what the future holds for biopharma in an AI-driven world.

Data is at the core of the life sciences and healthcare industries. Billions of digital records relating to areas such as drug development, clinical trials, competitive intelligence and real-world outcomes are critical to everyday decision-making.

But in the digital age, humans cannot physically read and digest every bit of information relevant to a given decision. In addition, almost every organization has what is called 'dark' or 'siloed' data – valuable data that is not being used, or that organizations don’t know they have. It is estimated that as much as 90% of the data within a given organization is dark or siloed. As a result, pharmaceutical companies are making important decisions with incomplete information.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK